ADMINISTRATIVE AND OUTREACH CORE: ABSTRACT The PANUC Administrative and Outreach (Admin) Core has overall responsibility for scientific direction and leadership of our integrated and collaborative multi-site and multidisciplinary center of excellence for research and training. The Center Director and Administrator, in full collaboration with the Advisory Committees and Executive Committee, coordinate and integrate PANUC components, activities, and resources in pursuit of our vision of precision medicine for cognitive impairment in PD. Our Admin Core innovates by seamlessly linking of all major PD-focused research, clinical, outreach, and education efforts in the Pacific Northwest: PANUC, PD Biomarker Program (U01 NS082137), Northwest PD Research Education and Clinical Center (PADRECC), Parkinson's Center of OR, Parkinson's Genetic Research (PaGeR), UW Medicine Memory &Brain Wellness Clinic, and WA PD Registry. The Admin Core actively supports PANUC's mission to train the next generation of PD researchers by promoting the academic careers of trainees and junior faculty as well as focusing established investigators on precision medicine for cognitive impairment in PD. It promotes productive interactions with local, national, and international investigators and research programs focused on PD as part of PANUC's goal to be an effective point of information for investigators and the general public. In addition, the Admin Core ensures that all PANUC investigators and trainees are knowledgeable and fully compliant with human subject, animal welfare, scientific integrity, and NIH, university, VA, and State of Washington or Oregon conduct of scientific research policy requirements.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center (P50)
Project #
2P50NS062684-06
Application #
8881523
Study Section
Special Emphasis Panel (ZNS1-SRB-J (07))
Project Start
2008-07-01
Project End
2015-07-31
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
6
Fiscal Year
2014
Total Cost
$122,763
Indirect Cost
$43,305
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Smulders, Katrijn; Dale, Marian L; Carlson-Kuhta, Patricia et al. (2016) Pharmacological treatment in Parkinson's disease: Effects on gait. Parkinsonism Relat Disord 31:3-13
Wang, Liyong; Maldonado, Lizmarie; Beecham, Gary W et al. (2016) DNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient. Neurol Genet 2:e72
Mata, Ignacio F; Leverenz, James B; Weintraub, Daniel et al. (2016) GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 31:95-102
Mata, Ignacio F; Davis, Marie Y; Lopez, Alexis N et al. (2016) The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. Am J Med Genet B Neuropsychiatr Genet 171:925-30
Costa-Mallen, Paola; Zabetian, Cyrus P; Hu, Shu-Ching et al. (2016) Smoking and haptoglobin phenotype modulate serum ferritin and haptoglobin levels in Parkinson disease. J Neural Transm (Vienna) 123:1319-1330
Moelter, Stephen T; Weintraub, Daniel; Mace, Lauren et al. (2016) Research consent capacity varies with executive function and memory in Parkinson's disease. Mov Disord 31:414-7
Cholerton, Brenna; Larson, Eric B; Quinn, Joseph F et al. (2016) Precision Medicine: Clarity for the Complexity of Dementia. Am J Pathol 186:500-6
Davis, Marie Y; Johnson, Catherine O; Leverenz, James B et al. (2016) Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurol 73:1217-1224
Costa-Mallen, Paola; Zabetian, Cyrus P; Agarwal, Pinky et al. (2016) Response to the letter "Haptoglobin phenotype and Parkinson disease risk" by Delanghe et al. Parkinsonism Relat Disord 22:110-1
Crane, Paul K; Gibbons, Laura E; Dams-O'Connor, Kristen et al. (2016) Association of Traumatic Brain Injury With Late-Life Neurodegenerative Conditions and Neuropathologic Findings. JAMA Neurol 73:1062-9

Showing the most recent 10 out of 151 publications